The Program Project for marrow transplantation in leukemia and genetic blood disorders is an integrated multidisciplinary program of basic and clinical research aimed at elucidating genetic, biologic and pharmacologic factors which influence the development of transplanted hematopoietic and lymphoid progenitor cells within an allogeneic host, and the donor and host cell interactions which foster or prevent engraftment, hematopoietic and immunologic reconstitution, and the emergence of graft-host tolerance, or GvHD, or relapse of leukemia. Specific objectives of the Program Project include: 1) Evaluation of T-cell depleted marrow transplants and their potential to abrogate GvHD and improve disease-free survival in both HLA-identical and HLA-disparate leukemic hosts. 2) Definition of cells, cell systems and cell products affecting the growth and development of transplanted hematopoietic progenitor cell populations depleted of T cells within an allogeneic host. 3) Development and evaluation of new therapies designed to foster the early reconstitution of resistance to infections within the transplanted host and 4) The development and evaluation of new cytoreductive regimens designed to more effective by eradicate leukemic cells and facilitate engraftment of allogeneic marrow cells while reducing damage to host cell systems necessary to sustain the patient and support the development of the marrow graft. Considerable progress has been made in each of these target areas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA023766-08
Application #
3093065
Study Section
Clinical Cancer Program Project Review Committee (CCP)
Project Start
1978-08-01
Project End
1988-07-31
Budget Start
1985-08-01
Budget End
1986-07-31
Support Year
8
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Boudreau, Jeanette E; Hsu, Katharine C (2018) Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned. Trends Immunol 39:222-239
Lin, Richard J; Ho, Caleb; Hilden, Patrick D et al. (2018) Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol :
Malard, Florent; Labopin, Myriam; Cho, Christina et al. (2018) Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC. J Hematol Oncol 11:127
Luduec, Jean-BenoƮt Le; Kudva, Anupa; Boudreau, Jeanette E et al. (2018) Novel multiplex PCR-SSP method for centromeric KIR allele discrimination. Sci Rep 8:14853
Shah, Gunjan L; Moskowitz, Craig H (2018) Transplant strategies in relapsed/refractory Hodgkin lymphoma. Blood 131:1689-1697
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Staffas, Anna; Burgos da Silva, Marina; Slingerland, Ann E et al. (2018) Nutritional Support from the Intestinal Microbiota Improves Hematopoietic Reconstitution after Bone Marrow Transplantation in Mice. Cell Host Microbe 23:447-457.e4
Velardi, Enrico; Tsai, Jennifer J; Radtke, Stefan et al. (2018) Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. Nat Med 24:239-246
Moskowitz, Craig H (2018) Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv 2:821-824
Kim, Seong Jin; Huang, Yao-Ting; Foldi, Julia et al. (2018) Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 20:e12881

Showing the most recent 10 out of 452 publications